Kapitalmarknadsdag 2022

Tid

Program

15:00

Welcome
Lars Frick
Moderator

15:05

Cereno’s Commitment to Transforming Cardiovascular Disease Management
Sten R. Sörensen
CEO, Cereno

15:20

Overview of Cardiovascular Disease and Cereno’s Focus Areas
Dr. Björn Dahlöf
CMO, Cereno

15:30

Understanding PAH: Debilitating Rare Disease
Dr. Raymond Benza
Prof. and Director at the Ohio State University Wexner Medical Center; PI of Phase II study with CS1

15:45

Clinical Phase II Study Design with CS1
Dr. Raymond Benza
Prof. and Director at the Ohio State University Wexner Medical Center; PI of Phase II study with CS1

15:50

CardioMEMS – Phase II Clinical Collaboration Between Abbott and Cereno
Dr. Phil Adamson
Divisional Vice President and Chief Medical Office Heart Failure Division, Abbott

16:05

Cereno’s Drug Candidate CS1 to Treat PAH and Broader Potential
Dr. Björn Dahlöf
CMO, Cereno

16:20

Cereno’s Preclinical Candidates Potential to Break New Ground
Dr. Björn Dahlöf
CMO, Cereno

16:25

CS585 – A First-In-Class Compound Targeting the IP Receptor for Prevention of Thrombosis Without Increased Risk of Bleeding
Dr. Michael Holinstat
Ass. Prof. at University of Michigan Medical School; and Director Translation Research, Cereno

16:40

CS014 – A Novel HDAC Inhibitor Regulating Platelet Activity, Fbrinolysis and Clot Stability for Prevention of Thrombosis Without Increased Risk of Bleeding
Dr. Michael Holinstat
Ass. Prof. at University of Michigan Medical School; and Director Translation Research, Cereno

16:55

Panel: The Need for True Innovation in CVD Management – Focus on PAH and Thrombosis

Moderated by moderator

Dr. Björn Dahlöf
Dr. Gunnar Olsson
Dr. Michael Holinstat
Dr. Phil Adamson

17:10

Questions from Audience
Moderated by moderator

17:20

Concluding Words
Sten R. Sörensen
CEO, Cereno